Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 3

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Authors Escudier B, Cosaert J, Jethwa S

Published 12 September 2008 Volume 2008:2(3) Pages 517—530

DOI https://doi.org/10.2147/BTT.S3509

Review by Single-blind

Peer reviewer comments 1


Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa2

1Unité Immunothérapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, Switzerland

Abstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in patients with treatment-naïve metastatic RCC receiving bevacizumab combined with IFN compared with IFN. The dose of IFN, which was initiated at 9 MIU 3 times a week in these trials, can be reduced to effectively manage IFN-related side effects without compromising the efficacy of bevacizumab plus IFN. Bevacizumab has good tolerability with manageable side effects, both alone and in combination with other agents; the tolerability profile of bevacizumab in combination with IFN is consistent with the well-characterized and well-established profiles of these therapies. The tolerability of bevacizumab combined with IFN and the flexibility to manage IFN-related side effects are important considerations when selecting first-line therapy. With a number of options now available for RCC therapy, optimizing their use is a key consideration in improving patient benefit.

Keywords: bevacizumab (Avastin®), interferon alpha, efficacy, tolerability, renal cell carcinoma (RCC), low-dose interferon

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]